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Abstract
Background: We hypothesized that cleavage of the extracellular matrix (ECM) proteoglycans versican and aggrecan by
ADAMTS (a disintegrin and metalloprotease with thrombospondin motifs) proteases, which contributes to stress-induced
ECM-reorganization in atherogenesis and osteoarthritis, also play a role in heart failure development.
Objectives: The primary objective was to identify alterations in expression of ADAMTS versicanases and aggrecanases
during development of heart failure, while evaluation of the effects of in vivo modulation of relevant changes in ADAMTS
activity constituted the secondary objective.
Methods: Myocardial levels of versican, aggrecan, and their ADAMTS cleaving proteases were examined in Wistar rats six
weeks after aortic banding (AB), and versican and selected ADAMTS versicanases were further analyzed in neonatal
cardiomyocytes (NCM) and cardiac fibroblasts (NFB) after stimulation by inflammatory mediators. Based on the initial
findings, ADAMTS4 was selected the most promising therapeutic target. Thus, rats with AB were treated with pentosan
polysulfate (PPS), a polysaccharide with known ADAMTS4-inhibitory properties, and effects on versican fragmentation, left
ventricular function and geometry were evaluated.
Results: We discovered that myocardial mRNA and protein levels of ADAMTS1 and -4, and mRNA levels of versican,
aggrecan, and ADAMTS8 increased after AB, and TNF-a and IL-1b synergistically increased mRNA of versican and ADAMTS4
in NCM and NFB and secretion of ADAMTS4 from NCM. Furthermore, PPS-treatment improved systolic function,
demonstrated by an improved fractional shortening (vehicle 4863% versus PPS 6061%, p,0.01) after AB. Following PPS-
treatment, we observed an ,80% reduction in myocardial ADAMTS4 mRNA (p= 0.03), and ,50% reduction in the
extracellular amount of the p150 versican fragments (p = 0.05), suggesting reduced versicanase activity.
Conclusions: Our findings suggest that AB induces an increase in myocardial ADAMTS4 versicanase activity, and that PPS-
treatment improved systolic function in the pressure-overloaded heart, holding promise as a novel therapeutic agent in
heart failure.
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Introduction
The fatal development of remodeling and failure of the
pressure-overloaded heart is insufficiently prevented by today’s
therapy. Extracellular matrix (ECM) reorganization is gaining
recognition as an important contributor to heart failure progres-
sion [1], and inhibitors of matrix metalloproteases (MMP)
modulating collagen turnover have been extensively studied in
the search for novel and effective heart failure drugs [2]. However,
promising pre-clinical results have not been translated into clinical
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benefits [3]. Thus, other ECM components should be evaluated as
targets for heart failure therapy, and the family of proteoglycans,
where some members are associated with heart failure develop-
ment [4,5], represent potential candidates.
Although it has been shown that the large hydrophilic
proteoglycans versican and aggrecan reside in the embryonic
cardiac ECM [6], and that versican is expressed in cardiomyocytes
[7] and the adult heart [8], their role in heart failure development
is unknown. In other organs, versican and aggrecan are important
regulators of ECM volume and hydration due to their large
content of water-binding glucosaminoglycan (GAG) chains, and
their ability to aggregate with the GAG molecule hyaluronic acid
(HA) [9]. The degradation of versican and aggrecan by ADAMTS
(a disintegrin and metalloprotease with thrombospondin motifs)
proteases is essential in ECM reorganization in both pathological
and physiological processes, including osteoarthritis, atherosclero-
sis, and regulation of cardiac organogenesis [10–13]. Interestingly,
ADAMTS4 synthesis in macrophages increases in response to
tumor necrosis factor (TNF)-a and interleukin (IL)-1b [14],
cytokines which are found increased in the myocardium of heart
failure patients [15,16], suggesting a role in heart failure
development.
The primary objective of the study was to identify alterations in
expression of ADAMTS versicanases and aggrecanases during
development of heart failure. Myocardial levels of versican,
aggrecan, and their cleaving ADAMTS proteases were examined
in rats exposed to aortic banding (AB), subdivided into groups with
preserved (HFpFS) or reduced (HFrFS) fractional shortening (FS).
Versican and selected ADAMTS proteases were further analyzed
in neonatal cardiomyocytes (NCM) and cardiac fibroblasts (NFB)
after treatment with inflammatory mediators. The secondary
objective of the study was to evaluate the effects of in vivo
modulation of relevant changes in ADAMTS activity. Based on
the initial findings, we identified ADAMTS4 as the most
promising target among the ADAMTS proteases. Therefore, rats
with AB were treated with pentosan polysulfate (PPS), a
polysaccharide with known ADAMTS4-inhibitory properties
[17,18], and effects on heart function, versican expression level
and fragmentation were studied.
Materials and Methods
Ethics statement
The experimental procedures conformed to the European
Convention for the Protection of Vertebrate Animals Used for Experimental
and Other Scientific Purposes, and are reported according to the
ARRIVE guidelines. The protocols were approved by the
Norwegian Council for Animal Research prior to the beginning
of the study. All surgical procedures were performed in full
anesthesia by an investigator with extensive experience in rodent
experimental models (JMA), and all efforts were made to minimize
suffering.
Animal model
Male Wistar rats weighing 160–170 grams (approximately 7
weeks old) (Taconic, Skensved Denmark) underwent AB essen-
tially as described previously [19]. Briefly, the ascending aorta was
dissected free through a right hemithoracotomy, and ligated (3-0
silk) against a steel wire. The sham-operated rats were subjected to
the same surgical procedure with a loose suture around the aorta.
In all surgical procedures performed, a mixture of 67% N2O, 28%
O2, and 4% isoflurane in an anesthesia chamber was used for
preoperative sedation. To maintain anesthesia peroperatively, a
mixture of 69% N2O, 29% O2, and 2% isoflurane was given by
the endotracheal tube and the animals were ventilated on a
respirator (Zoovent, Triumph Technical Services, Milton Keynes,
UK). Buprenorphine (0.2 mg/kg) was given as postoperative
analgesia after AB. Rats were housed in cages (two rats in each
cage) with Bee Kay bedding (Scanbur BK, Nittedal, Norway) in
55% humidity on a 12 h light/dark cycle, with food pellets (RM1,
801151, Scanbur BK) and water ad libitum.
Animal phenotyping and administration of PPS in AB rat
model
In vivo heart function was evaluated using the Vevo2100 system
(Visualsonics Inc, Canada) as previously described [20]. Thereaf-
ter, the heart was excised under deep anesthesia, washed in saline
and blotted dry to remove blood in the cardiac chambers. The
heart chambers were separated by rapid dissection, before left
ventricles were snap-frozen in liquid nitrogen and stored at270uC
until RNA and protein analyses.
In the first part of the study, myocardial samples were harvested
six weeks after induction of AB, and rats were divided into
subgroups with preserved (HFpFS) or reduced FS (HFrFS),
defined as FS above or below 50% based on findings from
previous studies [19] Inclusion criteria were based on echocar-
diographic and post-mortem analysis as follows: Inclusion criteria
for HFrFS group were increased lung weight (.2.5 g), increased
posterior wall thickness at diastole (.2.0 mm), and increased left
atrial diameter (.5.0 mm), while criteria for inclusion in the
HFpFS group were increased posterior wall thickness at diastole
(.2.0 mm), increased left ventricular weight (.0.75 g), and
preserved lung weight (,2.0 g). Animals not satisfying inclusion
criteria were excluded from the study. Based on power analysis,
inclusion of minimum six rats in each group could detect a $2-
fold increase in mRNA levels (power 0.8, a= 0.05).
For administration of PPS, rats were stratified to an intervention
or control group, pairing two and two rats with similar gradient
over the stenosis measured at post-operative day 3, in order to
ensure similar degree of cardiac stress. The intervention group was
treated with 6 mg/kg of sodium PPS (Interfarm AS, Norway),
while a control group received vehicle (0.9% NaCl), both injected
subcutaneously every third day. The dosage was selected based on
previous experimental studies exploring other effects of PPS-
treatment [21–23], and recommended dosage regimens for human
and veterinary medicine assuming a bio-availability of PPS close to
heparin for subcutaneous injections. Rats were observed daily and
no side effects including hemorrhage were observed. Six weeks
after AB or sham operation, rats were examined by echocardiog-
raphy and post-mortem analysis, performed by experienced
investigators (IS, JMA) blinded to treatment group. In addition,
mRNA and protein analyses on myocardial tissue were performed
blinded to treatment group. Power analysis revealed that a
minimum of 14 rats in each AB-group could detect a $8%
increase in FS in rats receiving PPS-treatment compared to
vehicle-treatment (power 0.8, a= 0.05).
RNA isolation, reverse transcription and qRT-PCR
The mRNA levels of ADAMTS1, -4, -5, and -20, possessing
versicanase and/or aggrecanase activity and ADAMTS8, -9, -15, -
16, and -18 possessing aggrecanase activity [24] were quantified in
rat left ventricle by qRT-PCR. ADAMTS demonstrating altered
mRNA levels after AB were also quantified after PPS-treatment.
In addition, mRNA levels of proteins known to modulate
ADAMTS activity or versican function were measured; tissue
inhibitor metalloprotease (TIMP)-3, HA synthase-1 and -2, and
membrane-type (MT)4-MMP, while mRNA levels of versican and
Pentosan Polysulfate in Heart Failure
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the versicanases ADAMTS1 and -4 were quantified in NFB and
NCM.
Total RNA was isolated from the left ventricle in AB rats, rat
NCM and NFB (RNeasy mini kit, Qiagen, Valencia, CA). All RNA
samples were quality assessed, with RNA integrity numbers (RIN).
7.5 (Agilent Bioanalyzer, Agilent Technologies, Palo Alto, CA, USA)
and 280/260 ratios .2 (Nanodrop ND-1000 Spectrophotometer
(Thermo Scientific, IL) accepted. Reverse transcription was
performed with iScript Select cDNA Synthesis Kit (Bio-Rad
Laboratories, Inc., Hercules, CA). Pre-designed TaqMan assays
(Applied Biosystems, Foster City, CA) were used in quantitative real-
time polymerase chain reaction (qPCR) to determine gene
expression of ADAMTS1 (Rn01646120_g1), ADAMTS4
(Rn02103282_s1), ADAMTS5 (Rn01458486_m1), ADAMTS8
(Rn01524921_m1), ADAMTS9 (Rn01425216_m1), ADAMTS15
(Rn01524703_m1), ADAMTS16 (Rn01537448_m1), ADAMTS18
(Rn01426916_m1), ADAMTS20 (Rn01407540_m1), versican
(Rn01493755_m1), aggrecan (Rn00573424_m1), HAS-1
(Rn01455687_g1), HAS-2 (Rn00565774_m1), TIMP-3
(Rn00441826_m1) and MT4-MMP (Mm00449292_m1). For nor-
malization, the reference gene ribosomal protein L4 (RPL4)
(Rn008211091_g1) was used. Results were detected on a 7900HT
Fast Real Time PCR System (Applied Biosystems, CA).
Protein isolation
Frozen left ventricle from the HFpFS , HFrFS and correspond-
ing sham group, was pulverized in a mortar with liquid nitrogen.
Ice cold lysis buffer (20 mM Hepes pH 7.5, 150 mM NaCl, 1 mM
EDTA, 0.5% Triton X-100) with protease inhibitors (Complete
EDTA-free tablets, Roche Diagnostics, Germany) was added and
the samples homogenized for 361 minutes with a Polytron 1200
(Capitol Scientific, Austin, TX), incubated on ice for 30 minutes
and centrifuged at 70 000 g for 60 minutes at 4uC. The
supernatants were stored at 270u.
Fractional protein isolation
Fractional protein lysates from myocardium of rats with AB
treated with PPS or vehicle were extracted as previously described
[25]. Briefly, proteins were separated into three fractions; NaCl-
soluble extracellular proteins (NaCl-ECM) and guanidine-soluble
extracellular proteins (G-ECM), containing the fluid and matrix
compartment of ECM respectively, in addition to cellular and cell-
linked proteins soluble in SDS (SDS-samples). NaCl-ECM and G-
ECM were deglycosylated using 4 mU/NaCl-sample and 12 mU/
G-sample of Chondroitinase ABC (from Proteus vulgaris, G3667,
Sigma-Aldrich, MO) and 5 mU/NaCl-sample and 15 mU/G-
sample of keratanase (endo-b-galactosidase from Bacteroides
fragilis, G6920, Sigma-Aldrich), essentially as previously described
[25].
Immunoblotting
Protein concentrations were measured using the Micro BCA
Protein Assay Kit (Pierce/Thermo Scientific, IL). Sample buffer
was mixed with 30 mg (NaCl and SDS samples) or 5–25 mg (G-
Figure 1. Elevated mRNA levels of ADAMTS1, -4 and-8 in rats after aortic banding. Myocardial mRNA expression of ADAMTS versicanases
and aggrecanases in rats with preserved (HFpFS, n = 9) or reduced FS (HFrFS, n = 6) six weeks after AB, normalized to reference gene RPL4 and relative
to sham (n = 9). Box-plots show median (horizontal line), interquartile range (box), 1.5xinterquartile range or maximum/minimum range (whiskers)
and outliers (.1.5xinterquartile range). *p,0.05. AB, aortic banding; FS, fractional shortening; ribosomal protein L4, RPL4.
doi:10.1371/journal.pone.0089621.g001
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samples) of the protein lysate, denatured at 96uC for 10 min, and
run on 1.5 mm 4–12% Bis-Tris gradient gels (Nupage, Invitrogen,
CA), with MOPS SDS running buffer until the 37 kDa protein
marker reached the bottom of the gel. All protein extracts were
loaded blinded to group.
SDS-PAGE and immunoblotting was performed as described in
the Criterion BioRad protocol, using polyvinylidene fluoride
(PVDF) membranes (GE Healthcare Life Sciences, Uppsala,
Sweden). Blots were developed using the ECL Plus Western
Blotting Detection System (GE Healthcare), visualized in the Las-
4000 mini from Fujifilm (Japan) and quantified using ImageJ
software (NIH). Before reprobing, stripping was performed using
the Restore Western Blot Stripping Buffer (21059, Thermo
Scientific, IL).
Coomassie staining of the blots was chosen to control for equal
loading in fractional protein lysates, while anti-glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) (sc-20357, Santa Cruz
Biotechnology) was used as loading control for protein lysates
from HFpFS, HFrFS and the corresponding sham group. Equal
loading was observed for GAPDH, and for Coomassie for SDS
and NaCl protein fraction samples. For G-fractions, Coomassie
staining revealed signs of potential unequal loading, thus protein
levels in these samples were normalized to the 65 kDa band in the
corresponding Coomassie stained blot.
Antibodies
Primary antibody used was versican fragment displaying the
neo-epitope DPEEAE resulting from cleavage by ADAMTS1/4
[26] (ab19345, Abcam, Cambrigde, UK) or ADAMTS4 (PAI-175,
Thermo Scientific, IL), and secondary antibody used was goat
anti-rabbit IgG-HRP (4030-05, Southern Biotech, AL), diluted in
1% casein (versican DPEEAE and secondary antibody) or 5%
non-fat dry-milk (170-6404, BioRad) (ADAMTS4). Membranes
were blocked in 1% casein for one hour in room temperature,
incubated overnight at 4uC with primary antibody, and for one
hour in room temperature with secondary antibody.
Neonatal cardiomyocytes and fibroblasts
Primary neonatal cardiomyocytes (NCM) and fibroblasts (NFB)
were isolated from 1–3 day old Wistar rats (Taconic, Skensved,
Denmark) as previously described [5]. Briefly, hearts were
removed and the left ventricle dissected and digested using
collagenase, and cell suspension was transferred to uncoated
culture flasks allowing NFB to attach, while NCM were transferred
to gelatin-coated culture dishes (Corning International, Corning,
NY) in plating medium [Dulbecco’s Modified Eagles Medium
(Sigma) supplemented with penicillin/streptomycin (Sigma),
44 mmol l21 NaHCO, medium 199 (Sigma), 26 mmol l21
NaHCO3, horse serum (14-703E, Bio-Whittaker,Walkersville,
ML) and fetal calf serum (14-701E, Bio-Whittaker)]. Cardiac cells
were starved in serum-free medium (plating medium without
serum) 24 hours before treatment with 10 ng/ml IL-1b (501-RL-
Table 1. Echocardiographic analyses and organ weights in AB-rats.
Sham HFpFS
Sham vs HFpFS
(p-value) HFrFS
Sham vs HFrFS
(p-value)
HFpFS vs HFrFS (p-
value)
N 9 9 6
ORGAN WEIGHTS
Body (g) 36766 330614 0.11 329612 0.01 0.65
Heart (g) 0.9960.03 1.59 6 0.07 ,0.01 2.7760.13 ,0.01 ,0.01
LV (g) 0.5260.02 0.9660.04 ,0.01 1.3460.06 ,0.01 ,0.01
RV (g) 0.1560.01 0.1560.01 1.00 0.3360.04 ,0.01 ,0.01
Lung (g) 1.0560.07 1.5660.07 ,0.01 3.8260.19 ,0.01 ,0.01
M-MODE LV
IVSd (mm) 1.4660.04 2.3760.10 ,0.01 2.4760.03 ,0.01 0.46
LVDd (mm) 6.2560.14 5.7160.20 0.04 7.7160.29 ,0.01 ,0.01
LVDs (mm) 2.6960.16 2.1760.13 0.03 5.0060.25 ,0.01 ,0.01
FS (%) 5762 6262 0.10 3562 ,0.01 ,0.01
PWd (mm) 1.6260.04 2.4260.07 ,0.01 2.5460.05 ,0.01 0.20
M-MODE AO/LA
LAD (mm) 3.4260.06 4.3260.08 ,0.01 6.5760.37 ,0.01 ,0.01
Aorta (mm) 2.5360.04 2.5660.03 0.56 2.5860.05 0.43 0.73
DOPPLER
Peak mitral flow (m/s) 834634 854642 0.71 1094663 ,0.01 ,0.01
Mitral deceleration (m/s) 23686149 32886236 ,0.01 54056437 ,0.01 ,0.01
Heart rate 41468 42069 0.65 37867 ,0.01 ,0.01
TISSUE DOPPLER
Maximal systolic velocity 7763 5262 ,0.01 3161 ,0.01 ,0.01
Maximal diastolic velocity 8563 243610 ,0.01 24963 ,0.01 0.63
AB, aortic banding; hypertrophy; HF, heart failure; IVSd, interventricular septal end-diastolic dimension; LVDd, left ventricular diameter at end-diastole; LVDs, left
ventricular diameter at end-systole; FS, fractional shortening; PWd, posterior wall dimension; LAD, left atrial diameter.
doi:10.1371/journal.pone.0089621.t001
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010, R&D Systems, Minneapolis, MN) and 50 ng/ml TNF-a
(PMC3014, BioSource International, Camarillo, CA) separately
and combined, and 1000 ng/ml lipopolysaccharide (LPS) (List
laboratories, Campbell, CA) for 24 h. Cell medium was ultra-
filtrated using Amicon Ultra-4 10 kDa centrifugal filter (Millipore,
MA) before protein analyses.
Statistical analyses
Depending on the distribution, data are reported as mean6-
SEM or median (interquartile range) and comparisons between
groups investigated with Student’s t-test or Mann-Whitney test.
Mortality rates were compared using Pearson’s Chi Square test. P-
values (two-sided) #0.05 were considered significant. Dunn’s
correction for multiple comparisons was used for cell culture
mRNA data. Data are normalized to RPL4 and control (mRNA)
or control (protein).
Results
Myocardial expression of ADAMTS versicanases is
increased in rats after AB
Myocardial mRNA levels of ADAMTS proteases with known
versican and/or aggrecan activity were measured in the two
subgroups of AB-rats (animal characteristics are given in Table 1).
In addition to included rats, 3 rats died before reaching post-
operative week 6. ADAMTS1, and -4, with known versicanase
Figure 2. Increased protein expression of ADAMTS1 and -4 after aortic banding. Myocardial protein expression of ADAMTS1 (A) and -4 (B)
in rats with preserved (HFpFS, n = 9) or reduced FS (HFrFS, n = 6) six weeks after aortic banding. Box-plots show median (horizontal line), interquartile
range (box), 1.5xinterquartile range or maximum/minimum range (whiskers) and outliers (.1.5xinterquartile range). *p,0.05. AB, aortic banding; FS,
fractional shortening.
doi:10.1371/journal.pone.0089621.g002
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and aggrecanase activity, and ADAMTS8 with known aggreca-
nase activity, demonstrated enhanced mRNA levels in AB-rats
with reduced FS. More specific, ADAMTS1 mRNA level was 1.7-
fold higher in HFrFS (1.74 (1.51–1.99)) than in both HFpFS (1.00
(0.80–1.01), p,0.01) and sham (1.00 (0.80–1.30), p,0.01), while
ADAMTS4 mRNA level in HFrFS (8.75 (3.97–38.21), p,0.01)
was ,9-fold higher than sham (1.00 (0.95–1.11), p,0.01) and 5-
fold higher than HFpFS (1.65 (1.44–2.88), p = 0.01). Similarly,
mRNA levels of ADAMTS8 mRNA in HFrFS (10.22 (7.00–19.36)
were ,10-fold higher than sham (1.00 (0.66–1.53), p,0.01) and
,2-fold higher than HFpFS (5.44 (4.04–6.64), p,0.01) (Figure 1).
Immunoblots of myocardial lysates from rats with AB were
analyzed in order to evaluate protein levels of the proforms and
mature forms of ADAMTS1 and24 [27,28]. In the HFrFS group,
Figure 3. Elevated mRNA levels of versican and aggrecan in rats after aortic banding. Myocardial mRNA expression of versican and
aggrecan in rats with preserved (HFpFS, n = 9) or reduced FS (HFrFS, n = 6) six weeks after AB, normalized to the reference gene RPL4 and relative to
sham (n= 9). Box-plots show median (horizontal line), interquartile range (box), 1.5xinterquartile range or maximum/minimum range (whiskers) and
outliers (.1.5xinterquartile range). *p,0.05. AB, aortic banding; FS, fractional shortening; ribosomal protein L4, RPL4.
doi:10.1371/journal.pone.0089621.g003
Figure 4. Myocardial TIMP-3, HAS and MT4-MMP mRNA levels in rats after aortic banding. Myocardial mRNA expression of TIMP-3, HAS
and MT4-MMP in rats with preserved (HFpFS, n = 9) or reduced FS (HFrFS, n = 6) six weeks after aortic banding, normalized to the reference gene
ribosomal protein L4 (RPL4) and relative to sham (n= 9). Box-plots show median (horizontal line), interquartile range (box), 1.5xinterquartile range or
maximum/minimum range (whiskers) and outliers (.1.5xinterquartile range). *p,0.05. AB, aortic banding; FS, fractional shortening; TIMP, tissue
inhibitor metalloprotease; HAS, hyaluronic acid synthase; MT, membrane-type.
doi:10.1371/journal.pone.0089621.g004
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level of mature membrane-associated p87 form (1.66 (1.25–2.76))
and mature secreted p65 form (1.78 (1.59–2.06)) were all higher
than in sham (p87: 1.00 (0.91–1.29), p = 0.03; p65: 1.00 (0.85–
1.07), p,0.01) (Figure 2A). Furthermore, the p65 fragment
expression was higher in HFpFS (1.64 (1.12–2.10) than in sham
(p = 0.03), while no significant alterations was observed for the
p110 proform (sham 1.00 (0.92–1.42, HFpFS 1.84 (0.60–3.00),
HFrFS 1.66 (0.82-.56)). For ADAMTS4, the protein level of both
the p100 proform and the mature membrane-associated p68 form
was higher in the HFpFS (p100: 3.37 (2.02–4.30), p,0.01; p68:
1.41 (1.24–1.57), p = 0.03) and HFrFS group (p100: 5.55 (3.09–
9.07), p,0.01; p68: 1.44 (1.32–1.59), p,0.01), than in sham
(p100: 1.00 (0.48–1.08); p68: 1.00 (0.94–1.02)) (Figure 2B). The
p53 form was not clearly visualized in the western blots.
Myocardial mRNA levels of versican and aggrecan are
increased in rats after AB
Versican and aggrecan mRNA levels increased after AB
(Figure 3). Compared to the versican level in sham (1.00 (0.92–
1.55), a 3.5-fold increase in HFrFS (3.46 (3.11–4.58), p,0.01),and
a tendency towards higher levels in HFpFS (1.49 (1.25–2.10,
p = 0.06), were observed, in addition to a 2.3-fold increase in
HFrFS compared to HFpFS (p,0.01). Similarly, the aggrecan
level increased 4-fold in HFpFS (3.35 (2.55–5.98), p,0.01) and 6-
fold in HFrFS (5.78 (4.65–14.38), p,0.01) compared to sham
levels (1.00 (0.57–1.30). However, we did not observe any
significant increase in aggrecan mRNA levels after transition to
failure (HFpFS vs HFrFS: p = 0.16).
Figure 5. ADAMTS4 and versican mRNA in cardiac fibroblasts and cardiomyocytes was induced by inflammatory mediators. mRNA
in NFB and NCM of ADAMTS1 (A,B), ADAMTS4 (C,D), and versican (E,F) after stimulation with LPS (n = 6), IL-1b (n = 7), TNF-a (n = 10 (NCM)/6 (NFB)),
separate and combined (n = 7 (NCM)/4 (NFB)). Untreated cells served as control (n = 15 (NCM)/18 (NFB)). Box-plots show median (horizontal line),
interquartile range (box), 1.5xinterquartile range or maximum/minimum range (whiskers) and outliers (.1.5xinterquartile range). *p,0.05, compared
to control. NFB, neonatal fibroblasts; NCM, neonatal cardiomyocytes; LPS, lipopolysaccharide; IL, interleukin; TNF, tumor necrosis factor.
doi:10.1371/journal.pone.0089621.g005
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Myocardial mRNA levels of MT4-MMP and HAS increased
in rats after AB
Levels of TIMP-3, the endogenous inhibitor of ADAMTS4
[29], remained unchanged after AB (Figure 4A), whereas levels of
MT4-MMP, which activates ADAMTS4 [28], were higher in
HFrFS (1.69 (1.21–2.29) than in HFpFS (0.88 (0.57–1.23),
p = 0.03) (Figure 4B). In HFrFS, we also found higher expressions
of HAS-1 (4.55 (3.98–9.11)) and -2 (1.75 (1.37–2.82)) than in sham
(HAS-1: 1.00 (0.75–1.18), p,0.01), HAS-2: 1.00 (0.66–1.33),
p = 0.01) (Figure 4C).
ADAMTS4 and versican levels were altered by pro-
inflammatory mediators in cardiac cells
mRNA levels of versican and the two versicanases found
increased in HFrFS-rats, namely ADAMTS1 and -4, were
examined in NCM and NFB after treatment with inflammatory
mediators. ADAMTS1 mRNA expression was lower in NFB
treated with LPS, TNF-a alone and in combination with IL-1b
(Figure 5A), and lower in TNF-a-treated NCM, than in control
(Figure 5B). ADAMTS4 mRNA, on the other hand, increased
after LPS- and IL-1b-treatment, and after combined stimulation
with TNF-a and IL-1b in NFB (Figure 5C), while IL-1b and TNF-
a in combination increased the ADAMTS4 level in NCM
(Figure 5D). Similarly, versican levels increased in response to
LPS, IL-1b alone and in combination with TNF-a in NFB
(Figure 5E). In NCM, IL-1b alone and combined with TNF-a,
induced enhancement in versican mRNA levels (Figure 5F).
To assess secretion of active isoforms of ADAMTS4, we
examined the protein level of ADAMTS4 in cell medium after
stimulation with the identified inducers of mRNA synthesis,
namely LPS, IL-1b alone and in combination with TNF-a. In
NCM, enhanced levels of the mature membrane-associated p68
fragment was induced by IL-1b alone and in combination with
TNF-a, while the mature secreted p53 fragment was induced by
the combined stimulation of IL-1b and TNF-a only. The level of
p68 isoform reduced in response to IL-1b alone (Figure 6). LPS
reduced the level of p68 isoform in both cell types (data not
shown). We did not identify the p53 isoform in NFB media.
Improved heart function in AB-rats treated with PPS
Among the two ADAMTS versicanases, ADAMTS1 and -4,
that were upregulated in HFrFS, we considered ADAMTS4 a
better target for treatment due to the pronounced increase in
HFrFS-rats, and inflammation-induced increase in cardiac cells.
The semisynthetic polysaccharide PPS has known ADAMTS4
inhibitory effects [17,18], and was thus chosen as an ADAMTS4-
inhibitor for in vivo studies.
Interestingly, PPS-treated AB-rats demonstrated enhanced
contractile function compared to vehicle-treated rats (Table 2).
Briefly, we observed a 25% higher fractional shortening (FS), and
a 33% lower left ventricular diameter in systole, in PPS-treated
than in vehicle-treated AB-rats. Furthermore, a tendency towards
lower lung weight in PPS-treated than in vehicle-treated AB-rats
was observed (p = 0.13)
However, no significant alterations were observed for diastolic
function, including mitral deceleration, peak mitral flow, left atrial
diameter, or maximal diastolic velocity. Parameters for hypertro-
phy was not affected either by PPS-treatment in rats after AB
(Table 2). The mortality rate was similar in both treatment groups
(vehicle: 8/24 vs PPS: 6/22, p = 0.66).
PPS-treatment reduced myocardial ADAMTS4 mRNA
levels
ADAMTS4 mRNA level was reduced in AB-rats treated with
PPS (1.29 (1.00–6.45)) compared to vehicle-treated AB-rats (6.03
(3.79–12.76), p = 0.03) (Figure 7). On the contrary, PPS-treatment
Figure 6. Altered ADAMTS4 protein levels in cell medium from cardiac cells after stimulation with inflammatory mediators. Protein
levels of ADAMTS4 active forms (p68 and p53) in cell medium after stimulation of IL-1b alone (NFB n=4, NCM n=3) and in combination with TNF-a
(NFB n= 3, NCM n= 4), relative to controls (n = 4). The bars represent mean levels and the error bars SEM. *p,0.05. NFB, neonatal fibroblasts; NCM,
neonatal cardiomyocytes; LPS, lipopolysaccharide; IL, interleukin; TNF, tumor necrosis factor.
doi:10.1371/journal.pone.0089621.g006
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did not alter the mRNA levels of versican (vehicle 2.28 (1.67–2.77),
PPS 2.46 (1.31–3.23), p = 0.85), or the versicanases ADAMTS1
(vehicle 1.41 (1.10–1.72), PPS 1.22 (0.91–1.58), p = 0.70) or -5
(vehicle 1.26 (1.04–1.94), PPS 1.70 (1.24–2.10), p = 0.40). Neither
the mRNA levels of aggrecan (vehicle 9.10 (1.69–14.84), PPS 3.93
(1.71–7.30), p = 0.17) nor the aggrecanase ADAMTS8 (vehicle
2.77 (1.87-5-12), PPS 4.63 (1.74–13.52), p = 0.27) were affected by
PPS treatment (Figure 8).
PPS treatment did not affect mRNA levels of proteins known to
modulate versican or ADAMTS4 activity, namely HAS-1 (ctr 3.02
(2.79–5.60), PPS 2.70 (0.75–4.07), p = 0.77), HAS-2 (ctr 1.47
(1.39–2.52), PPS 1.11 (0.85–1.59), p = 0.38), TIMP-3 ((ctr 1.35
(1.23–1.44), PPS 1.09 (0.87–1.42), p = 0.92), or MT4-MMP levels
((ctr 1.56 (0.93–2.15), PPS 1.27 (0.99–2.05), p = 0.83) (Figure 8).
PPS-treatment inhibited myocardial versican cleavage in
AB-rats
Presence of versican fragmentation was evaluated by immuno-
blotting using an antibody detecting the neo-epitope DPEAAE
displayed after cleavage of versican by ADAMTS1/4, where
fragments of 150 and 70 kDa result from cleavage of the V0 and
V1 isoform, respectively [25,26]. In NaCl-ECM, we observed a
higher amount of p150 versican in vehicle-treated AB (2.14 (1.34–
3.55)) than in vehicle-treated sham (1.06 (0.73–1.30), p = 0.04).
Following PPS-treatment, the levels of p150 versican in NaCl-
ECM were reduced by ,50% (1.08 (0.69–1.63)) compared to
vehicle-treated AB-rats (p = 0.05). A tendency towards higher
amounts of the p70-fragment in NaCl-ECM in vehicle-treated AB-
rats (1.08 (1.02–1.21) than in both PPS-treated AB-rats (0.97
(0.90–1.07), p = 0.14) and vehicle-treated sham rats (0.95 (0.90–
1.05), p = 0.11) were observed (Figure 9).
Discussion
In this study, we discovered that PPS-treatment improved
systolic function in the pressure -overloaded heart. Our findings
suggest that this beneficial effect of PPS was mediated through a
reduction in ADAMTS4 versicanase activity, based on the
following main findings: 1) increased ADAMTS4 expression and
altered ADAMTS-induced versican degradation during heart
failure development, 2) inflammation-induced ADAMTS4 and
versican synthesis in cardiac cells, and 3) improved contractile
performance accompanied by indications of reduced ADAMTS4
versicanase activity in AB-rats receiving PPS. In summary, our
findings shed light on a novel mechanism for heart failure
development, and a promising novel heart failure therapy.
Enhanced ADAMTS activity during heart failure
development
To the best of our knowledge, we are the first to report
increased synthesis and activity of ADAMTS versicanases and
aggrecanases during heart failure progression. First, in the
myocardium of AB-rats with reduced FS, an increase in mRNA
synthesis of ADAMTS1, -4 and -8, and enhanced protein levels of
ADAMTS1 and -4, was observed, concurrent with an increase in
the ADAMTS4 activating enzyme MT4-MMP. In addition,
mRNA synthesis of versican and aggrecan increased, providing
substrate for ADAMTS-mediated fragmentation.
Synthesis of ADAMTS4 and versican in cardiac cells was
induced in vitro by TNF-a and IL-1b, cytokines found in enhanced
levels in the failing myocardium [15,16], suggesting inflammation
as a trigger for ADAMTS-mediated versican fragmentation in
heart failure. Secretion of active isoforms of ADAMTS4 was also
enhanced in cardiomyocytes after combined stimulation of IL-1b
and TNF-a, whereas the increases in cellular levels in fibroblasts
were not followed by increased secretion of the enzyme.
Nevertheless, we regard both cardiomyocytes and fibroblasts as
potential sources for ADAMTS4, and believe that our findings in
cell culture reflect a sophisticated regulation of ADAMTS4
production and activation, involving cell-specific and synergistic
effects within a complex cytokine milieu that are difficult to
reproduce in vitro. Indeed, the post-translational processing of
ADAMTS4 is known to involve several steps and modulatory
factors; the activation of p68 isoform through prodomain removal
and activation of p53 isoform through C-truncation is mediated by
furin and MT4-MMP, respectively, while several other mediators,
like TIMP, may also modulate processing [28], enabling distinct
regulation of the various processing steps.
The notion of accelerated ADAMTS-induced versicanase
activity in response to pressure overload was supported by
increased amounts of versican p150 DPEEAE fragments resulting
from ADAMTS1/4-induced cleavage. After AB, the amount of
versican p150 fragment doubled in NaCl-ECM, the fluid-
compartment of the ECM. Interestingly, ADAMTS4 lacks the
thrombospondin repeat tail that links other ADAMTS proteases to
ECM components [30], suggesting that ADAMTS4 is located in
the NaCl-soluble ECM. Taken together, the observed accumula-
Figure 7. Decreased myocardial ADAMTS4 mRNA level after
PPS-treatment. Myocardial mRNA expression of ADAMTS4 in rats
treated with PPS (n = 10) or vehicle (n = 7) six weeks after AB, and in
sham-operated rats treated with PPS (n = 3) normalized to the reference
gene RPL4 and relative to vehicle-treated sham (n= 3). Box-plots show
median (horizontal line), interquartile range (box), 1.5xinterquartile
range or maximum/minimum range (whiskers) and outliers (.
1.5xinterquartile range). *p,0.05. AB, aortic banding; PPS, pentosan
polysulfate; HF, heart failure; RPL4, ribosomal protein L4.
doi:10.1371/journal.pone.0089621.g007
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tion of p150 versican fragments is probably caused, at least
partially, by an accelerated ADAMTS4 activity.
PPS-treatment reduced myocardial ADAMTS4
versicanase activity
PPS-treatment of AB-rats counteracted several of the alterations
in ADAMTS4 and versican fragment levels observed in vehicle-
treated AB-rats. While previous studies have demonstrated that
PPS inhibits aggrecanase activity of ADAMTS4 and -5 [17]
without affecting gene expression of the protease [18], we did
observe reduced mRNA levels of ADAMTS4 after PPS-treatment.
However, reduced expression of ADAMTS5 has been observed in
PPS-treated rats [22], supporting that inhibitory actions of PPS
also can be mediated through reduced enzyme expression.
Interestingly, the level of TIMP-3 was not affected, resulting in a
net increase of the protease to inhibitor ratio. Indeed, downreg-
ulation of p150 DPEEAE versican fragments in NaCl-ECM in
PPS-treated AB-rats supports that PPS inhibit ADAMTS4
versicanase activity in the pressure-overloaded heart.
Figure 8. Myocardial mRNA levels after PPS treatment in rats after aortic banding. Myocardial mRNA expression of ADAMTS1, -5, -8 (A),
versican, aggrecan (B), HAS-1, -2, TIMP-3, and MT4-MMP (C) in rats treated with PPS (n = 9 or 10) or vehicle (n = 7 or 9) six weeks after AB, and sham-
operated rats treated with PPS (n = 3 or 4) normalized to the reference gene ribosomal protein L4 (RPL4) and relative to vehicle-treated sham (n= 3).
The bars represent median levels and the error bars the 75th percentile. *p,0.05. HF, heart failure, HA, hyaluronic acid.
doi:10.1371/journal.pone.0089621.g008
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PPS-treatment improved contractile function in AB-rats
PPS-treatment improved contractile function in rats after AB,
potentially halting the critical phase of transition to failure. The
concurrent reduction in ADAMTS4 expression and amount of
versican p150 fragments observed after PPS-treatment, suggests an
association between versican degradation and deterioration of
systolic function. Versican enables cartilage to resist compression
by reducing fluid movements [31], and its viscoelastic properties
are likely to be important also in myocardial mechanics regarding
the repetitive cycles of contraction and relaxation. The accumu-
lation of versican p150 fragments in the NaCl-ECM observed in
our study could reflect an unfavorable increase in myocardial
water content, at least in some compartments of the ECM. Indeed,
heart failure is associated with myocardial edema [32], and
enhanced interstitial hydration may compromise systolic function
and attenuate oxygen delivery [33–35]. Interestingly, swelling of
ECM due to versican accumulation exerts detrimental effects in
other organs; breakdown of versican in lungs worsen lung edema
[36], while accumulation of versican contributes to the increased
ECM volume that occurs during formation of atherosclerotic
plaques [37]. In addition, degradation of versican may also
potentially disrupt the proteoglycan-rich endothelial glycocalyx,
resulting in increased vascular permeability and myocardial edema
[38,39]. However, the contribution of versican degradation to
myocardial mechanics remains insufficiently explored and merits
further elucidation in future studies.
As opposed to collagens, proteoglycans provide limited tensile
strength [40] and their contribution to passive stiffness could
therefore be minor, thus supporting the lack of diastolic alterations
in PPS-treated animals. Unknown extracardiac effects of PPS
potentially affecting afterload may also serve as an explanation to
the selective effective on systolic function. Taken together, PPS-
treatment seems to enhance systolic function by modulating
myocardial mechanics in a manner that maintains diastolic
function.
Figure 9. Versican p150 fragment level was reduced after PPS-treatment in rats with aortic banding. Myocardial levels of p150 (A) and
p70 (B) versican DPEEAE fragment in NaCl-soluble ECM of rats subjected to AB with or without PPS-treatment, shown as representative immunoblot
and box-plots with median (horizontal line), interquartile range (box), 1.5xinterquartile range or maximum/minimum range (whiskers) and outliers (.
1.5xinterquartile range). *p,0.05. AB, aortic banding; PPS, pentosan polysulfate; ECM, extracellular matrix; HF, heart failure.
doi:10.1371/journal.pone.0089621.g009
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Clinical implications
ADAMTS4 represents a promising novel therapeutic target in
patients with aortic stenosis. PPS has FDA-approval, and is used in
treatment of interstitial cystitis patients and osteoarthritis in
veterinary medicine. While PPS reduces infarction size in a
reperfusion model [41], its potential as a target in chronic heart
failure has not previously been explored. PPS is well tolerated and
besides a mild anti-coagulative effect, PPS exerts few side effects
[42]. Thus, PPS holds promise as a novel therapeutic agent in
heart failure.
Limitations of the study
Further studies are needed to establish the cause-effect
relationship between PPS, ADAMTS4-inhibition and improved
contractile performance. Due to the lack of opportunity to
subdivide AB-rats into the failing and non-failing phenotype
during in vivo ADAMTS4-inhibition, the rats with AB receiving
vehicle- or PPS-treatment should be regarded as a group
consisting of both phenotypes. Although PPS-treatment led to a
significant improvement in parameters for systolic function, the
heterogeneity within the group regarding heart failure develop-
ment could render the study underpowered to detect other
pathophysiological characteristics, such as left atrial diameter and
lung weight. Studying the effects of PPS-treatment at different
time-points after induction of pressure overload may reveal effects
on these pathophysiological characteristics, but is beyond the
scope of this study. Furthermore, ADAMTS4-independent effects
of PPS need to be explored in further detail in future studies. PPS
also suppresses the activity of ADAMTS5 [17], inflammatory
mediators, and coagulation factors [41], effects that may
contribute to the observed beneficial effect in the pressure-
overloaded heart. The role of aggrecanase activity exerted by
ADAMTS1, -4, and -8 in heart failure progression will hopefully
also be addressed in studies to come.
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